- Conditions
- Peripheral Nerve Block, Anxiety, Preoperative Anxiety
- Interventions
- Music, Midazolam
- Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Systemic Juvenile Idiopathic Arthritis With Active Flare
- Interventions
- canakinumab, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Still´s Disease
- Interventions
- MAS825
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Portland, Oregon
- Conditions
- Diabetes Mellitus, Metabolic Integrity
- Interventions
- Humulin, Humalog, Novolog
- Procedure
- Lead sponsor
- Global Infusion and Aspiration Systems, LLC
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Batesville, Mississippi
- Conditions
- Arthritis Juvenile Idiopathic
- Interventions
- In open-label phase: treatment with tofacitinib, In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Rilonacept
- Biological
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Months to 19 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Fetal Growth Restriction (FGR), Placental Insufficiency, Preeclampsia, Still Births, Pregnancy, Pregnancy Complications, Pregnancy Outcomes, Ultrasound
- Interventions
- ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS)
- Device
- Lead sponsor
- Carilion Clinic
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities
- Interventions
- Observational Intervention
- Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Upadacitinib, Tocilizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Valhalla, New York + 3 more
- Conditions
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Interventions
- ACZ885 150 mg (Canakinumab)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Columbus, Ohio
- Conditions
- Food Allergy
- Interventions
- Food Supplement
- Dietary Supplement
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 5 Months to 11 Months
- Enrollment
- 705 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
- Interventions
- Chart review
- Other
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 6 Months to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Atlanta, Georgia • Cincinnati, Ohio + 1 more
- Conditions
- Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
- Interventions
- tocilizumab
- Biological
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
- Interventions
- Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
- Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 2 Months to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Stage 4 Liver Cancer
- Interventions
- bulletin board or telephone depth interview (TDI), interview regarding experiences and opinions as to condition and treatment
- Behavioral
- Lead sponsor
- Find A Cure Panel
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Pancreas Cancer, Melanoma
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
- Interventions
- Emapalumab
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 6 Months to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more
- Conditions
- Adult Onset Still's Disease
- Interventions
- Camoteskimab (CERC-007, AVTX-007, AEVI-007)
- Drug
- Lead sponsor
- Apollo Therapeutics Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Ann Arbor, Michigan
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more